跳至主要内容
临床试验/NCT00030043
NCT00030043已完成1 期

Penetrating Auditory Brainstem Implant for Neurofibromatosis 2

FDA Office of Orphan Products Development4 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2001年9月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10
试验地点
4

研究概览

简要总结

This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.

详细描述

Neurofibromatosis Type 2 (NF2) is characterized by multiple tumors of the cranial and spinal nerves, and, in particular, by bilateral acoustic tumors. Surgical resection of these tumors generally results in the transection of the VIIIth nerve, destruction of the cochlea and auditory nerve, and total hearing loss. Due to the loss of the auditory nerve, these patients are not candidates for cochlear implantation. The Auditory Brainstem Implant (ABI) provides the only available intervention to restore some auditory sensation to these patients. An ABI is an implantable prosthesis that produces sound sensation by electrical stimulation of the ascending auditory pathway at the level of the cochlear nucleus.

The PABI may be placed surgically during tumor resection. Efficacy will be assessed using psychophysical and standard speech reception measures.

研究设计

研究类型
Interventional
分配方式
Non Randomized
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of neurofibromatosis type 2
  • Speak English as a primary language

排除标准

  • Physical, psychological, or medical conditions that contraindicate the surgical procedure

研究者

发起方
FDA Office of Orphan Products Development
申办方类型
Fed

研究点 (4)

Loading locations...

相似试验